Literature DB >> 28941733

"30-minute-delta" of high-sensitivity troponin I improves diagnostic performance in acute myocardial infarction.

Hiroaki Yokoyama1, Takumi Higuma2, Tomohide Endo1, Fumie Nishizaki1, Kenji Hanada1, Takashi Yokota1, Masahiro Yamada1, Ken Okumura3, Hirofumi Tomita4.   

Abstract

BACKGROUND: Rapid and accurate diagnosis of acute myocardial infarction (AMI) are critical for the initiation of effective medical treatment. Recently, a high-sensitivity cardiac troponin I (hs-cTnI) assay was developed as a biochemical marker for the early diagnosis of AMI. Current guidelines recommend that serial measurements of cardiac troponin should be performed in patients who present symptoms suggestive of acute coronary syndrome. The aim of this study was to evaluate the diagnostic performance of 30-minute serial measurements of hs-cTnI for the detection of AMI.
METHODS: We prospectively enrolled patients presenting with suspected AMI within 12h from symptom onset. We measured hs-cTnI levels at presentation and 30min later to calculate the "30-minute-delta". The diagnostic performance was determined by the area under the receiver operating characteristic curve (AUC).
RESULTS: Among the 71 patients enrolled in this study, 55 (77%) were diagnosed with AMI. The hs-cTnI level at presentation was significantly greater in the patients with AMI than in those without AMI [306.2 (77.3-1809.9)pg/mL versus 22.5 (7.2-115.5)pg/mL, p<0.01]. The "30-minute-delta" was also significantly greater in patients with AMI [54.6 (13.5-288.0)pg/mL versus 1.9 (0.6-6.3)pg/mL, p<0.01]. The AUC of the "30-minute-delta" was significantly greater than that of a single measurement at presentation (0.911 versus 0.829, p<0.05).
CONCLUSIONS: The "30-minute-delta" of hs-cTnI presents improved diagnostic performance for AMI compared with a single measurement.
Copyright © 2017 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; High-sensitivity cardiac troponin I; Serial measurements; “30-minute-delta”

Mesh:

Substances:

Year:  2017        PMID: 28941733     DOI: 10.1016/j.jjcc.2017.08.003

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  5 in total

1.  A cardiac troponin I study in a minimally invasive myocardial infarction canine model.

Authors:  Reyaj Mikrani; Cuilan Liang; Muhammad Naveed; Asghar Ali Kamboh; Muhammad Abbas; Birendra Chaurasiya; Li Xue; Zhou Xiaohui
Journal:  J Appl Biomed       Date:  2018-11-23       Impact factor: 1.797

Review 2.  Absolute Versus Relative Changes in Cardiac Troponins in the Diagnosis of Myocardial Infarction: A Systematic Review and Meta-Analysis.

Authors:  Anvesh Ravanavena; Chetna Ravindra; Emmanuelar O Igweonu-Nwakile; Safina Ali; Salomi Paul; Shreyas Yakkali; Sneha Teresa Selvin; Sonu Thomas; Viktoriya Bikeyeva; Ahmed Abdullah; Aleksandra Radivojevic; Anas A Abu Jad; Prachi Balani
Journal:  Cureus       Date:  2022-07-28

3.  Rapid use of high-sensitive cardiac troponin I for ruling-in and ruling-out of acute myocardial infarction (RACING-MI): study protocol.

Authors:  Camilla Bang; Camilla Hansen; Kasper Glerup Lauridsen; Christian Alcaraz Frederiksen; Morten Schmidt; Tage Jensen; Nete Hornung; Bo Løfgren
Journal:  Open Heart       Date:  2019-04-03

4.  Absolute Change in High-Sensitivity Cardiac Troponin I at Three Hours After Presentation is Useful for Diagnosing Acute Myocardial Infarction in the Emergency Department.

Authors:  Jong Won Kim; Hanah Kim; Yeo-Min Yun; Kyeong Ryong Lee; Hyun Joong Kim
Journal:  Ann Lab Med       Date:  2020-06-17       Impact factor: 3.464

5.  Absolute Change in High Sensitivity Cardiac Troponin I for Three Hours is Useful for Diagnosing Acute Myocardial Infarction in the Emergency Department: How to Get to Best Benefit From HS-Troponins in Clinical Practice?

Authors:  Fabien Huet; Anne Marie Dupuy; Jean Paul Cristol; François Roubille
Journal:  Ann Lab Med       Date:  2020-06-17       Impact factor: 3.464

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.